Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × pCR Rate × Docetaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 237 Carcinoma, Non-Small-Cell Lung 204 Prostatic Neoplasms 137 Lung Neoplasms 96 Stomach Neoplasms 85 Head and Neck Neoplasms 57 Squamous Cell Carcinoma of Head and Neck 56 Neoplasms 42 Neoplasm Metastasis 39 Esophageal Neoplasms 36 Ovarian Neoplasms 29 Pancreatic Neoplasms 27 Sarcoma 19 Urinary Bladder Neoplasms 18 Adenocarcinoma of Lung 18 Carcinoma, Squamous Cell 17 Triple Negative Breast Neoplasms 15 Nasopharyngeal Carcinoma 14 Adenocarcinoma 14 Carcinoma, Ovarian Epithelial 13 Adenocarcinoma Of Esophagus 13 Recurrence 12 Inflammatory Breast Neoplasms 10 Carcinoma, Transitional Cell 10 Breast Neoplasms, Male 10 Esophageal Squamous Cell Carcinoma 9 Laryngeal Neoplasms 8 Uterine Cervical Neoplasms 7 Nasopharyngeal Neoplasms 7 Leiomyosarcoma 7

Interventions

Metformin 1 Epirubicin 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01929811 2022-04-06

NeoMET

Shanghai Jiao Tong University School of Medicine

Phase 2 Terminated

pCR Rate

Data powered by HemOnc (CC BY 4.0) Colophon ⚡